Xarelto (rivaroxaban) is a leading oral anticoagulant developed by Bayer and Janssen and accounts for about 45 percent of the direct oral anticoagulant (DOAC) market. It is widely prescribed for indications such as heart failure, thrombosis of the deep veins (DVT), lung embolism (PE), and postoperative prevention. As of 2026, the drug is at a […]